Table 1.
GCL activity, GSH contents, GCLM, and GCLC protein expression in patients vs. controls in the Swiss sample
| Variable | N | Untreated |
t-BHQ |
||
|---|---|---|---|---|---|
| Controls | Patients | Controls | Patients | ||
| GCL activity | 25 | 0.250 ± 0.08 | 0.215 ± 0.06 | 0.847 ± 0.26 | 0.627 ± 0.16** |
| GSH content | 25 | 56.7 ± 8.0 | 53.6 ± 6.4 | 144.9 ± 21.5 | 136.3 ± 19.1 |
| GCLM | 26 | 62.3 ± 16.3 | 61.7 ± 11.3 | 108.0 ± 24.0 | 107.6 ± 24.1 |
| GCLC | 26 | 44.4 ± 12.3 | 34.5 ± 10.9** | 64.1 ± 17.5 | 45.4 ± 15.8*** |
N, number of tested subjects. Values are given as average and SD under untreated or t-BHQ-treated conditions. GSH content is expressed as nanomoles of GSH per milligram of protein, and GCL activity is expressed as nanomoles of GSH per minute per milligram of protein. GCLM and GCLC protein expressions are presented as α-tubulin corrected arbitrary units.
**, P < 0.01;
***, P < 0.001 vs. the respective controls were calculated using ANOVA test (two-tailed).